Sun Pharma rebounded from ₹1,636, with analyst Deepak Pal highlighting ₹1,600 as a strong support level. A buy-on-dip strategy is advised, with ₹1,750-₹1,760 as near-term targets and a stop-loss at ₹1,600. Fundamentals remain solid-FY24 revenue rose 12% to ₹49,505 crore, net profit hit ₹9,602 crore, and margins held at 27%.